Watching INTELLIGENT BIO SOLUTIONS INC.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planINTELLIGENT BIO SOLUTIONS INC.
ibs.incAI Executive Summary
AI-powered analysis of 10-K filing content
Intelligent Bio Solutions remains a pre-commercial-scale medical device company with a going concern qualification from its auditor and a history of significant losses since inception. The company executed a 1-for-10 reverse stock split in December 2025, signaling continued stock price and capital-raising pressure, while its flagship IFP drug-screening product remains unavailable in the U.S. pending FDA 510(k) clearance. Internal controls were reported as remediated in the current period after prior material weaknesses, which is a positive but does not offset the underlying liquidity and going-concern risks.
Red Flags Detected (8)
Explicit going concern qualification from independent auditor for FY2026
Company needs to raise additional capital to continue operations; financing may be dilutive or unavailable on favorable terms
History of significant losses since inception with no clear path to profitability disclosed
5 more red flags detected
Key Takeaways
Company's viability depends on securing additional financing; going concern doubt is a critical risk
IFP drug-screening system is the sole active commercial product, sold outside the U.S. only, creating revenue concentration risk
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.